The majority of deaths among patients with prostate cancer (PCa) occur following metastasis; therefore, there is a critical need for effective treatment of metastatic PCa. Epithelialmesenchymal transition (EMT) is vital in the early stage of cancer cell metastasis and CD147 has been
reported to be associated with various types of cancer. The goal of this study was to investigate the role of CD147 in the EMT of PCa cells via short hairpin (sh)RNAmediated knockdown of CD147 in lymph node carcinoma of the prostate (LNCaP) cells. Reverse transcriptionquantitative PCR and
western blotting were performed to examine gene and protein expression. Cell migration and invasion were detected using a Transwell assay. Cell Counting Kit8 assay was performed to investigate cell viability. The knockdown of CD147 in LNCaP cells (LNCaP/shCD147 cells) resulted in an increase
in the expression of Ecadherin (an epithelial marker), and a decrease in the expression of Ncadherin and vimentin (mesenchymal markers). Importantly, the downregulation of CD147 in LNCaP cells inhibited the expression levels of nuclear βcatenin and Snail, and phosphorylation of glycogen
synthase kinase (GSK)3β on Ser 9, and increased the expression of phosphorylated (p)βcatenin (Ser33/37/Thr41). Treatment with lithium chloride (LiCl), a Wnt/βcatenin pathway agonist or a GSK3β inhibitor, attenuated CD147 downregulationinduced pβcatenin (Ser33/37/Thr41)
expression, which resulted in the upregulation of βcatenin in the nucleus. LiCl treatment prompted βcateninmediated expression of target proteins such as Snail and vimentin in LNCaP/shCD147 cells, and prevented Ecadherin expression, a molecule downstream to Snail. In conclusion,
these findings revealed an important role of CD147 in the regulation of the invasive and metastatic potential of PCa cells. CD147, via modulation of the Wnt/βcatenin pathway, may be implicated in the regulation of EMT of PCa cells and could be a potential therapeutic target for PCa.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Immunology, Jilin Medical University, Yanji, Yanbian, Jilin 133002, P.R. China
Department of Immunology, Institute of Medicine, Yanbian University, Yanji, Yanbian, Jilin 133002, P.R. China
Department of Urology Surgery, Affiliated Hospital of Jilin Medical University, Jilin City, Jilin 132013, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites